BIOD-238 / Ipsen - LARVOL DELTA

Biodel: JMP Securities Healthcare Conference (Biodel) - Anticipated intellectual property protection in EU through 2025; Anticipated intellectual property protection in US through 2026

Anticipated patent expiry • Diabetes

Novel formulations BIOD-238 and BIOD-250 result in more rapid absorption and declines from peak than Humalog (EASD 2013) - Presentation time: Thu, Sep 26, 12:30 PM; Abstract #1028 ; P1, N=12; NCT01811849; Sponsor; Biodel; "The mean VAS score was numerically lower, but not significantly different for BIOD-250 compared to HU (2.7 ± 1.6 mm for BIOD-250 and 8.2 ± 4.5 mm for HU). The mean VAS score for BIOD-238 was significantly higher than that associated with HU (24.2 ± 7.0 mm, p=0.029 vs. HU)."

P1 data • Diabetes